Glenmark Pharmaceuticals Inc., USA is recalling 15,696 cartons of Rizatriptan Benzoate Orally Disintegrating Tablets (5mg and 10mg strengths). These medications, which are used to treat migraine headaches, are being recalled because they contain an impurity called N-Nitroso Desmethyl Rizatriptan at levels exceeding the FDA's acceptable limit. The recall includes specific lots of 18-count unit-dose cartons with expiration dates ranging from July 2024 to June 2025.
The impurity N-Nitroso Desmethyl Rizatriptan is a type of nitrosamine, which is classified as a potential carcinogen. Long-term exposure to these impurities above acceptable levels may increase the risk of developing cancer.
You have 2 options:
Recall #: D-0534-2024; Product of India; 2400 cartons affected.
Recall #: D-0535-2024; Product of India; 13296 cartons affected.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.